

# David Armstrong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8371846/publications.pdf>

Version: 2024-02-01

199  
papers

9,715  
citations

70961

41  
h-index

42291

92  
g-index

206  
all docs

206  
docs citations

206  
times ranked

9490  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. <i>Gastroenterology</i> , 2015, 149, 102-109.e6.	0.6	1,161
2	The Development and Validation of an Endoscopic Grading System for Barrett's Esophagus: The Prague C & M Criteria. <i>Gastroenterology</i> , 2006, 131, 1392-1399.	0.6	931
3	Consumption of fluid skim milk promotes greater muscle protein accretion after resistance exercise than does consumption of an isonitrogenous and isoenergetic soy-protein beverage. <i>American Journal of Clinical Nutrition</i> , 2007, 85, 1031-1040.	2.2	433
4	Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process. <i>Gastroenterology</i> , 2012, 143, 336-346.	0.6	365
5	The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic Hemostasis and Proton Pump Inhibition are Associated with Improved Outcomes in a Real-Life Setting. <i>American Journal of Gastroenterology</i> , 2004, 99, 1238-1246.	0.2	352
6	Clinical Practice Guidelines for the Use of Video Capsule Endoscopy. <i>Gastroenterology</i> , 2017, 152, 497-514.	0.6	306
7	Between Celiac Disease and Irritable Bowel Syndrome: The "No Man's Land" of Gluten Sensitivity. <i>American Journal of Gastroenterology</i> , 2009, 104, 1587-1594.	0.2	267
8	Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 332-341.	0.9	240
9	EUS: a meta-analysis of test performance in suspected choledocholithiasis. <i>Gastrointestinal Endoscopy</i> , 2008, 67, 235-244.	0.5	219
10	Canadian Consensus Conference on the Management of Gastroesophageal Reflux Disease in Adults "Update 2004. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2005, 19, 15-35.	1.8	204
11	Risk of Upper Gastrointestinal Bleeding With Selective Serotonin Reuptake Inhibitors With or Without Concurrent NonSteroidal Anti-Inflammatory Use: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 811-819.	0.2	176
12	World Gastroenterology Organisation Global Guidelines. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 467-478.	1.1	173
13	CMOS Image Sensors for High Speed Applications. <i>Sensors</i> , 2009, 9, 430-444.	2.1	154
14	A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 739-746.	1.9	143
15	Convolutional neural networks for medical image analysis: State-of-the-art, comparisons, improvement and perspectives. <i>Neurocomputing</i> , 2021, 444, 92-110.	3.5	143
16	Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 857-863.	0.8	113
17	A Randomized Trial Comparing Omeprazole, Ranitidine, Cisapride, or Placebo in Helicobacter pylori Negative, Primary Care Patients with Dyspepsia: The CADET-HN Study. <i>American Journal of Gastroenterology</i> , 2005, 100, 1477-1488.	0.2	111
18	Canadian Association of Gastroenterology Consensus Guidelines on Safety and Quality Indicators in Endoscopy. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 17-31.	1.8	100

#	ARTICLE	IF	CITATIONS
19	A Randomized Controlled Trial of Laparoscopic Nissen Fundoplication Versus Proton Pump Inhibitors for Treatment of Patients With Chronic Gastroesophageal Reflux Disease: One-Year Follow-Up. <i>Surgical Innovation</i> , 2006, 13, 238-249.	0.4	94
20	Safety of Adding Oats to a Gluten-Free Diet for Patients With Celiac Disease: Systematic Review and Meta-analysis of Clinical and Observational Studies. <i>Gastroenterology</i> , 2017, 153, 395-409.e3.	0.6	90
21	Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study <sup>1</sup> . <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 803-811.	1.9	89
22	The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 413-421.	1.9	87
23	Simple Clinical Predictors May Obviate Urgent Endoscopy in Selected Patients With Nonvariceal Upper Gastrointestinal Tract Bleeding. <i>Archives of Internal Medicine</i> , 2007, 167, 265.	4.3	87
24	A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for the treatment of patients with chronic gastroesophageal reflux disease (GERD): 3-year outcomes. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2011, 25, 2547-2554.	1.3	83
25	Esomeprazole 40 mg Once a Day in Patients with Functional Dyspepsia: The Randomized, Placebo-Controlled "ENTER" Trial. <i>American Journal of Gastroenterology</i> , 2006, 101, 2096-2106.	0.2	79
26	Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 521-529.	1.9	75
27	Evidence-Based Recommendations for Short- and Long-Term Management of Uninvestigated Dyspepsia in Primary Care: An Update of the Canadian Dyspepsia Working Group (CanDys) Clinical Management Tool. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2005, 19, 285-303.	1.8	70
28	Review article: towards consistency in the endoscopic diagnosis of Barrett's oesophagus and columnar metaplasia. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 40-47.	1.9	69
29	Validation of the Rockall scoring system for outcomes from non-variceal upper gastrointestinal bleeding in a Canadian setting. <i>World Journal of Gastroenterology</i> , 2006, 12, 7779.	1.4	67
30	Effect on Intra-gastric pH of a PPI with a Prolonged Plasma Half-Life: Comparison between Tenatoprazole and Esomeprazole on the Duration of Acid Suppression in Healthy Male Volunteers. <i>American Journal of Gastroenterology</i> , 2005, 100, 1949-1956.	0.2	66
31	Evaluation and Management of Skeletal Health in Celiac Disease: Position Statement. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 819-829.	1.8	62
32	The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. <i>Drugs</i> , 2017, 77, 547-561.	4.9	62
33	Body-weight-support treadmill training improves blood glucose regulation in persons with incomplete spinal cord injury. <i>Journal of Applied Physiology</i> , 2004, 97, 716-724.	1.2	60
34	Injection of Botulinum Toxin a to Upper Esophageal Sphincter for Oropharyngeal Dysphagia in Two Patients with Inclusion Body Myositis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2004, 18, 397-399.	1.8	57
35	Evaluation of GERD Symptoms during Therapy. Part II. <i>Digestion</i> , 2004, 69, 238-244.	1.2	55
36	Review article: gastric pH - the most relevant predictor of benefit in reflux disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 19-26.	1.9	55

#	ARTICLE	IF	CITATIONS
37	An Interactive Web-Based Educational Tool Improves Detection and Delineation of Barrett's Esophagus-Related Neoplasia. <i>Gastroenterology</i> , 2019, 156, 1299-1308.e3.	0.6	55
38	Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care - the CADET-HR Study. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1189-1202.	1.9	53
39	Does the treatment of gastroesophageal reflux disease (GERD) meet patients' needs? A survey-based study. <i>Current Medical Research and Opinion</i> , 2006, 22, 657-662.	0.9	51
40	Resistance Training Reduces Fasted- and Fed-State Leucine Turnover and Increases Dietary Nitrogen Retention in Previously Untrained Young Men. <i>Journal of Nutrition</i> , 2007, 137, 985-991.	1.3	49
41	Inflammation-related differences in mucosa-associated microbiota and intestinal barrier function in colonic Crohn's disease. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G420-G431.	1.6	46
42	Access to Specialist Gastroenterology Care in Canada: The Practice Audit in Gastroenterology (PAGE) Wait Times Program. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2008, 22, 155-160.	1.8	44
43	Measuring Quality of Care in Patients With Nonvariceal Upper Gastrointestinal Hemorrhage: Development of an Explicit Quality Indicator Set. <i>American Journal of Gastroenterology</i> , 2010, 105, 1710-1718.	0.2	43
44	The prevalence of Barrett's oesophagus in a cohort of 1040 Canadian primary care patients with uninvestigated dyspepsia undergoing prompt endoscopy. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 595-599.	1.9	42
45	Characterization of Simultaneous Pressure Waves as Biomarkers for Colonic Motility Assessed by High-Resolution Colonic Manometry. <i>Frontiers in Physiology</i> , 2018, 9, 1248.	1.3	42
46	Predictors of treatment response in patients with non-erosive reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 371-376.	1.9	41
47	Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 187-199.	1.9	40
48	Access to Specialist Gastroenterology Care in Canada: Comparison of Wait Times and Consensus Targets. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2008, 22, 161-167.	1.8	40
49	Medical students' perceptions of nutrition education in Canadian universities. <i>Applied Physiology, Nutrition and Metabolism</i> , 2010, 35, 336-343.	0.9	40
50	Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 349-358.	1.9	39
51	Improvement of Lumbar Bone Mass after Infliximab Therapy in Crohn's Disease Patients. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2007, 21, 637-642.	1.8	39
52	Noninvasive Verification of Nasogastric Tube Placement Using a Magnetic Tracking System: A Pilot Study in Healthy Subjects. <i>Journal of Parenteral and Enteral Nutrition</i> , 2005, 29, 305-310.	1.3	37
53	Canadian Credentialing Guidelines for Colonoscopy. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2008, 22, 17-22.	1.8	37
54	The 2012 Sage Wait Times Program: Survey of Access to Gastroenterology in Canada. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2013, 27, 83-89.	1.8	37

#	ARTICLE	IF	CITATIONS
55	WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 1-11.	1.1	37
56	The Construction of a New Evaluative GERD Questionnaire – Methods and State of the Art. <i>Digestion</i> , 2004, 70, 71-78.	1.2	36
57	Systematic review: persistence and severity in gastroesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 841-853.	1.9	36
58	The Gain in Quality-Adjusted Life Months by Switching to Esomeprazole in Those With Continued Reflux Symptoms in Primary Care: EncompASS – A Cluster-Randomized Trial. <i>American Journal of Gastroenterology</i> , 2010, 105, 2341-2346.	0.2	36
59	What is the role of endoscopy and oesophageal biopsies in the management of GERD?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 373-385.	1.0	35
60	Omeprazole for Refractory Gastroesophageal Reflux Disease during Pregnancy and Lactation. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 1998, 12, 225-227.	1.8	34
61	Validation of the GSFO, a Self-Administered Symptom Frequency Questionnaire for Patients with Gastroesophageal Reflux Disease. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2003, 17, 307-312.	1.8	34
62	A Randomized Multicenter Trial to Evaluate Simple Utility Elicitation Techniques in Patients With Gastroesophageal Reflux Disease. <i>Medical Care</i> , 2004, 42, 1132-1142.	1.1	34
63	Bacterial overgrowth syndrome in myotonic muscular dystrophy is potentially treatable. <i>Muscle and Nerve</i> , 2010, 42, 853-855.	1.0	33
64	Changes in Home Parenteral Nutrition Practice Based on the Canadian Home Parenteral Nutrition Patient Registry. <i>Journal of Parenteral and Enteral Nutrition</i> , 2017, 41, 830-836.	1.3	33
65	The pharmacodynamics and pharmacokinetics of Etenoprazole 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 648-657.	1.9	32
66	Testing for Gluten-Related Disorders in Clinical Practice: The Role of Serology in Managing the Spectrum of Gluten Sensitivity. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2011, 25, 193-197.	1.8	32
67	The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD). <i>Pharmacoeconomics</i> , 2007, 25, 385-396.	1.7	31
68	Canadian Credentialing Guidelines for Endoscopic Retrograde Cholangiopancreatography. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2008, 22, 547-551.	1.8	31
69	Characterization of Serotonin Signaling Components in Patients with Inflammatory Bowel Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 132-140.	0.1	31
70	Cost-Utility of Laparoscopic Nissen Fundoplication versus Proton Pump Inhibitors for Chronic and Controlled Gastroesophageal Reflux Disease: A 3-Year Prospective Randomized Controlled Trial and Economic Evaluation. <i>Value in Health</i> , 2011, 14, 263-273.	0.1	30
71	A Literature Review of Quality in Lower Gastrointestinal Endoscopy from the Patient Perspective. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2011, 25, 681-685.	1.8	30
72	Gluten-Free Diet Reduces Symptoms, Particularly Diarrhea, in Patients With Irritable Bowel Syndrome and Antigliadin IgG. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2343-2352.e8.	2.4	30

#	ARTICLE	IF	CITATIONS
73	The Construction of a New Evaluative GERD Questionnaire – Methods and State of the Art. <i>Digestion</i> , 2007, 75, 17-24.	1.2	29
74	Epidemiology and Risk Factors for Bloodstream Infections in a Home Parenteral Nutrition Program. <i>Journal of Parenteral and Enteral Nutrition</i> , 2015, 39, 147-153.	1.3	29
75	Clinical Practice Guidelines for the Assessment of Uninvestigated Esophageal Dysphagia. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 5-19.	0.1	29
76	Symptom overlap in patients with upper gastrointestinal complaints in the Canadian confirmatory acid suppression test (CAST) study: further psychometric validation of the reflux disease questionnaire. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1087-1097.	1.9	28
77	Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 705-711.	1.9	27
78	Test-and-Treat Strategies for <i>Helicobacter pylori</i> in Uninvestigated Dyspepsia: A Canadian Economic Analysis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2000, 14, 379-388.	1.8	26
79	Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 1161-1169.	1.9	26
80	Determination of ReQuest <sub>®</sub> -Based Symptom Thresholds to Define Symptom Relief in GERD Clinical Studies. <i>Digestion</i> , 2005, 71, 145-151.	1.2	26
81	Canadian Home Parenteral Nutrition (HPN) Registry. <i>Journal of Parenteral and Enteral Nutrition</i> , 2012, 36, 407-414.	1.3	25
82	High Concentrations of Ammonia, But Not Volatile Amines, in Gastric Juice of Subjects with <i>Helicobacter pylori</i> Infection. <i>Helicobacter</i> , 1998, 3, 97-102.	1.6	24
83	Economic Analysis of Home vs Hospital-Based Parenteral Nutrition in Ontario, Canada. <i>Journal of Parenteral and Enteral Nutrition</i> , 2005, 29, 266-269.	1.3	24
84	Addition of glutamine to essential amino acids and carbohydrate does not enhance anabolism in young human males following exercise. <i>Applied Physiology, Nutrition and Metabolism</i> , 2006, 31, 518-529.	0.9	24
85	Malnutrition Matters in Canadian Hospitalized Patients. <i>Nutrition in Clinical Practice</i> , 2015, 30, 709-713.	1.1	24
86	Pantoprazole Rapidly Improves Health-Related Quality of Life in Patients With Heartburn. <i>Journal of Clinical Gastroenterology</i> , 2003, 37, 132-138.	1.1	23
87	A Comparison of Narrative and Table Formats for Presenting Hypothetical Health States to Patients with Gastrointestinal or Pulmonary Disease. <i>Medical Decision Making</i> , 2004, 24, 53-60.	1.2	23
88	The impact of illness in patients with moderate to severe gastro-esophageal reflux disease. <i>BMC Gastroenterology</i> , 2005, 5, 23.	0.8	23
89	Association Between Age and Complications After Outpatient Colonoscopy. <i>JAMA Network Open</i> , 2020, 3, e208958.	2.8	23
90	Low Prevalence of <i>Helicobacter Pylori</i> Infection in Canadian Children: A Cross-Sectional Analysis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2008, 22, 485-489.	1.8	22

#	ARTICLE	IF	CITATIONS
91	Genetic unexceptionalism: Clinician accounts of genetic testing for familial hypercholesterolaemia. <i>Social Science and Medicine</i> , 2010, 71, 910-917.	1.8	22
92	Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-11.	0.8	22
93	Approaches of integrating the development of guidelines and quality indicators: a systematic review. <i>BMC Health Services Research</i> , 2020, 20, 875.	0.9	22
94	Indicators of Safety Compromise in Gastrointestinal Endoscopy. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 71-78.	1.8	21
95	Effectiveness of disseminating consensus management recommendations for ulcer bleeding: a cluster randomized trial. <i>Cmaj</i> , 2013, 185, E156-E166.	0.9	21
96	Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 836-847.	0.9	21
97	Canadian Credentialing Guidelines for Endoscopic Privileges: An Overview. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2007, 21, 797-801.	1.8	20
98	Development of a catadioptric endoscope objective with forward and side views. <i>Journal of Biomedical Optics</i> , 2011, 16, 066015.	1.4	20
99	Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series. <i>Clinical Nutrition</i> , 2020, 39, 1774-1777.	2.3	19
100	Associations Between Colonic Motor Patterns and Autonomic Nervous System Activity Assessed by High-Resolution Manometry and Concurrent Heart Rate Variability. <i>Frontiers in Neuroscience</i> , 2019, 13, 1447.	1.4	19
101	Uniting the global gastroenterology community to meet the challenge of climate change and non-recyclable waste. <i>Gut</i> , 2021, 70, 2025-2029.	6.1	19
102	Validation of a Short Questionnaire in English and French for Use in Patients with Persistent Upper Gastrointestinal Symptoms Despite Proton Pump Inhibitor Therapy: The Pass (Proton Pump Inhibitor) Tj ETQq0 0 0 rgt /Overlock 10 TF		
103	<sup>13</sup> C Urea Breath Test for <i>Helicobacter pylori</i> : Determination of the Optimal Cut-Off Point in a Canadian Community Population. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2006, 20, 770-774.	1.8	18
104	Evaluation of densitometric bone-muscle relationships in Crohn's disease. <i>Bone</i> , 2007, 40, 1610-1614.	1.4	18
105	Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis -results from the maintenance phase of the EXPO study. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 1165-1171.	1.9	17
106	Point-of-Care, Peer-Comparator Colonoscopy Practice Audit: The Canadian Association of Gastroenterology Quality Program - Endoscopy. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2011, 25, 13-20.	1.8	17
107	Patient-Identified Quality Indicators for Colonoscopy Services. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2013, 27, 25-32.	1.8	17
108	GERD and Obesity: Is the Autonomic Nervous System the Missing Link?. <i>Critical Reviews in Biomedical Engineering</i> , 2014, 42, 17-24.	0.5	17

#	ARTICLE	IF	CITATIONS
109	Egyptian recommendations for management of Helicobacter pylori infection: 2018 report. Arab Journal of Gastroenterology, 2019, 20, 175-179.	0.4	17
110	The influence of demographic factors and health-related quality of life on treatment satisfaction in patients with gastroesophageal reflux disease treated with esomeprazole. Health and Quality of Life Outcomes, 2005, 3, 4.	1.0	16
111	Diarrhoea: interventions, consequences and epidemiology in the intensive care unit (DICE-ICU): a protocol for a prospective multicentre cohort study. BMJ Open, 2019, 9, e028237.	0.8	16
112	Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2019, 17, 1477-1488.e10.	2.4	16
113	Uniting the Global Gastroenterology Community to Meet the Challenge of Climate Change and Non-Recyclable Waste. Gastroenterology, 2021, 161, 1354-1360.	0.6	16
114	Practice Audit in Gastroenterology (Page) Program: A Novel Approach to Continuing Professional Development. Canadian Journal of Gastroenterology & Hepatology, 2006, 20, 405-410.	1.8	15
115	Joint Canadian Association of Gastroenterology and Crohn's Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology, 2020, 3, e1-e9.	0.1	15
116	Juvenile onset of Crohn's disease: A risk factor for reduced lumbar bone mass in premenopausal women. Bone, 2007, 40, 1290-1293.	1.4	14
117	Canadian Credentialing Guidelines for Esophagogastroduodenoscopy. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 349-354.	1.8	14
118	Summary of Guidelines for Infection Prevention and Control for Flexible Gastrointestinal Endoscopy. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 347-350.	1.8	14
119	Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Alimentary Pharmacology and Therapeutics, 2006, 25, 061116055830001-???	1.9	13
120	Photodynamic Therapy for Barrett's Esophagus with High-Grade Dysplasia: A Cost-Effectiveness Analysis. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 217-222.	1.8	13
121	Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis " results from the EXPO study. Alimentary Pharmacology and Therapeutics, 2009, 29, 959-966.	1.9	13
122	New Pharmacologic Approaches in Gastroesophageal Reflux Disease. Gastroenterology Clinics of North America, 2010, 39, 393-418.	1.0	13
123	Improving serological test ordering patterns for the diagnosis of celiac disease through clinical laboratory audit of practice. Clinical Biochemistry, 2012, 45, 455-459.	0.8	13
124	A Survey of the Practice of After-Hours and Emergency Endoscopy in Canada. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 871-876.	1.8	13
125	Novel Pharmaceutical Approaches to Reflux Disease. Gastroenterology Clinics of North America, 2013, 42, 93-117.	1.0	13
126	Gastroesophageal reflux disease. Current Opinion in Pharmacology, 2005, 5, 589-595.	1.7	12



#	ARTICLE	IF	CITATIONS
127	Validation of a symptom diary for patients with gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 531-541.	1.9	12
128	GERD Evaluation. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 237-241.	1.1	12
129	Barrett's esophagus: proton pump inhibitors and chemoprevention II. <i>Annals of the New York Academy of Sciences</i> , 2011, 1232, 114-139.	1.8	12
130	The Canadian Home Total Parenteral Nutrition (HTPN) Registry. <i>Journal of Parenteral and Enteral Nutrition</i> , 2012, 36, 415-420.	1.3	12
131	A Comparison of the Prevalence of Anxiety and Depression Between Uncomplicated and Complex IBD Patient Groups. <i>Gastroenterology Nursing</i> , 2018, 41, 427-435.	0.2	11
132	Bringing two worlds closer together: a critical analysis of an integrated approach to guideline development and quality assurance schemes. <i>BMC Health Services Research</i> , 2021, 21, 172.	0.9	11
133	Should patients with Barrett's oesophagus be kept under surveillance? The case for. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2008, 22, 721-739.	1.0	10
134	A Critical Assessment of the Current Status of Non-Erosive Reflux Disease. <i>Digestion</i> , 2008, 78, 46-54.	1.2	10
135	Specific HRQL instruments and symptom scores were more responsive than preference-based generic instruments in patients with GERD. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 102-110.	2.4	10
136	Personal Protective Equipment for Endoscopy in Low-Resource Settings During the COVID-19 Pandemic. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 833-840.	1.1	10
137	Survival of Patients With Shortâ€Bowel Syndrome on Home Parenteral Nutrition: A Prospective Cohort Study. <i>Journal of Parenteral and Enteral Nutrition</i> , 2021, 45, 1083-1088.	1.3	10
138	<sup>13</sup> C Urea Breath Test for <i>Helicobacter pylori</i> : Evaluation of 10-minute Breath Collection. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2006, 20, 775-778.	1.8	9
139	A One-Year Economic Evaluation of Six Alternative Strategies for the Management of Uninvestigated Upper Gastrointestinal Symptoms in Canadian Primary Care. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2010, 24, 489-498.	1.8	9
140	Safety of Esophagogastroduodenoscopy within 30 Days of Myocardial Infarction: A Retrospective Cohort Study from a Canadian Tertiary Centre. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 151-154.	1.8	9
141	The impact of intensifying acid suppression on sleep disturbance related to gastroâ€oesophageal reflux disease in primary care. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 730-737.	1.9	9
142	Management of reflux esophagitis: does the choice of proton pump inhibitor matter?. <i>International Journal of Clinical Practice</i> , 2015, 69, 796-801.	0.8	9
143	Getting fit for hip and knee replacement: a protocol for the Fit-Joints pilot randomized controlled trial of a multi-modal intervention in frail patients with osteoarthritis. <i>Pilot and Feasibility Studies</i> , 2018, 4, 127.	0.5	9
144	Guideline-based quality assurance: a conceptual framework for the definition of key elements. <i>BMC Health Services Research</i> , 2021, 21, 173.	0.9	9

#	ARTICLE	IF	CITATIONS
145	Determination of ReQuest <sup>TM</sup> -Based Symptom Thresholds to Define Symptom Relief in GERD Clinical Studies. <i>Digestion</i> , 2007, 75, 55-61.	1.2	8
146	Canadian Credentialing Guidelines for Flexible Sigmoidoscopy. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2008, 22, 115-119.	1.8	8
147	Deep Learning in Gastrointestinal Endoscopy. <i>Critical Reviews in Biomedical Engineering</i> , 2016, 44, 493-504.	0.5	8
148	Intravenous proton pump inhibitor therapy: a rationale for use. <i>Reviews in Gastroenterological Disorders</i> , 2005, 5 Suppl 2, S18-30.	0.6	8
149	Diarrhea during critical illness: a multicenter cohort study. <i>Intensive Care Medicine</i> , 2022, 48, 570-579.	3.9	8
150	Motion – All Patients with GERD Should Be Offered Once in a Lifetime Endoscopy: Arguments for the Motion. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2002, 16, 549-551.	1.8	7
151	The Effect of Sham Feeding on Neurocardiac Regulation in Healthy Human Volunteers. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2007, 21, 721-726.	1.8	7
152	Barrett's esophagus: histology and immunohistology. <i>Annals of the New York Academy of Sciences</i> , 2011, 1232, 76-92.	1.8	7
153	Proton pump inhibitors and gastric cancer: association is not causation. <i>Cut</i> , 2019, 68, 1529.2-1530.	6.1	7
154	Patients'™ Experiences and Challenges in Living with Inflammatory Bowel Disease: A Qualitative Approach. <i>Clinical and Experimental Gastroenterology</i> , 2021, Volume 14, 123-131.	1.0	7
155	The complexities of approaching nutrition in inflammatory bowel disease: current recommendations and future directions. <i>Nutrition Reviews</i> , 2022, 80, 215-229.	2.6	7
156	Early Relief of Upper Gastrointestinal Dyspeptic Symptoms: A Survey of Empirical Therapy with Pantoprazole in Canadian Clinical Practice. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2002, 16, 439-450.	1.8	6
157	An evidence-based, Latin-American consensus on gastro-oesophageal reflux disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 349-368.	0.8	6
158	Latin American Consensus on Gastroesophageal Reflux Disease: An Update on Therapy. <i>GastroenterologÅa Y HepatologÅa</i> , 2010, 33, 135-147.	0.2	6
159	Recent Trends in Breast, Cervical, and Colorectal Cancer Screening Test Utilization in Canada, Using Self-Reported Data from 2008 and 2012. <i>Current Oncology</i> , 2015, 22, 297-302.	0.9	6
160	Optical Biopsy of the Upper GI Tract Using Fluorescence Lifetime and Spectra. <i>Frontiers in Physiology</i> , 2020, 11, 339.	1.3	6
161	Evaluation of the Efficacy and Performance of Medical Implants: A Review. <i>Journal of Long-Term Effects of Medical Implants</i> , 2010, 20, 173-185.	0.2	6
162	Integrating Quality Assurance and Quality Improvement With Guidelines: Systematic Stakeholder-Driven Development of an Extension of the Guidelines International Network's™ McMaster Guideline Development Checklist. <i>Annals of Internal Medicine</i> , 2022, 175, 735-739.	2.0	6

#	ARTICLE	IF	CITATIONS
163	Rio de Janeiro Global Consensus on Landmarks, Definitions, and Classifications in Barrett's Esophagus: World Endoscopy Organization Delphi Study. <i>Gastroenterology</i> , 2022, 163, 84-96.e2.	0.6	6
164	5-aminolevulinic acid induced protoporphyrin IX as a fluorescence marker for quantitative image analysis of high-grade dysplasia in Barrett's esophagus cellular models. <i>Journal of Biomedical Optics</i> , 2015, 20, 036010.	1.4	5
165	Variations in practice patterns for adult cancer patients on home parenteral nutrition in Canada. <i>Nutrition</i> , 2019, 65, 27-32.	1.1	5
166	Symptom Assessment. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, S184-S192.	1.1	4
167	Quality Indicators for Colonoscopy: The Road Forward. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 242-242.	0.8	4
168	5-aminolevulinic acid for quantitative seek-and-treat of high-grade dysplasia in Barrett's esophagus cellular models. <i>Journal of Biomedical Optics</i> , 2015, 20, 028002.	1.4	4
169	Reduction in Anxiety and Depression Scores Associated with Improvement in Quality of Life in Patients with Inflammatory Bowel Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 12-17.	0.1	4
170	Home parenteral nutrition in older vs younger patients: Clinical characteristics and outcomes. <i>Journal of Parenteral and Enteral Nutrition</i> , 2022, 46, 348-356.	1.3	4
171	Uniting the Global Gastroenterology Community to Meet the Challenge of Climate Change and Nonrecyclable Waste. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 823-829.	1.1	4
172	Integrated CMOS Sensors for Fluorescence Spectroscopy and Imaging. , 2009, , .		3
173	Integrating Data from EHRs to Enhance Clinical Decision Making: The Inflammatory Bowel Disease Case. , 2014, , .		3
174	Anxiety, Depression and Quality of Life Improve After One Month and Three Months of Home Parenteral Nutrition: A Pilot Study in a Canadian Population. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 178-185.	0.1	3
175	Knowledge gaps in the management of refractory reflux-like symptoms: Healthcare provider survey. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14387.	1.6	3
176	Orocecal transit times (OCTT) in healthy subjects assessed by magnet-tracing (MT) and lactulose breath hydrogen test (LBHT). <i>Gastroenterology</i> , 2003, 124, A426.	0.6	2
177	Endoscopy and Quality Assurance "It is Here!". <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2007, 21, 255-256.	1.8	2
178	Report on the Expert Forum on using Information Technology to Facilitate Uptake and Impact of Colorectal Cancer Screening Guidelines. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 902-904.	1.8	2
179	Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 800-805.	0.6	2
180	Non-prescription proton-pump inhibitors for self-treating frequent heartburn: the role of the Canadian pharmacist. <i>Pharmacy Practice</i> , 2016, 14, 868.	0.8	2

#	ARTICLE	IF	CITATIONS
181	The GIN-McMaster guideline tool extension for the integration of quality improvement and quality assurance in guidelines: a description of the methods for its development. <i>Journal of Clinical Epidemiology</i> , 2023, 154, 197-203.	2.4	2
182	Does <i>Helicobacter pylori</i> infection and its eradication have any effect on heartburn and gastroesophageal reflux?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2004, 1, 16-17.	1.7	1
183	Response:. <i>Gastrointestinal Endoscopy</i> , 2008, 68, 810-811.	0.5	1
184	The Canadian Association of Gastroenterology Strategic Plan: Where Are We in 2014?. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 580-581.	0.8	1
185	Canadian Association of Gastroenterology: Strategic Plan 2016â€“2020. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-3.	0.8	1
186	Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after <i>Helicobacter pylori</i> Eradication. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 155-158.	0.1	1
187	An Electronic Clinical Decision-Making Tool for Patients with Suspected Colorectal Cancerâ€™ Preliminary Evaluation in Patients Presenting with Rectal Bleeding. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 204-209.	0.1	1
188	Psychological interventions for reducing anxiety in patients undergoing first-time colonoscopy. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	0.8	1
189	Home parenteral nutrition patients on mixed oil lipid emulsion have a higher rate of hospitalizations compare to those on soybean oilâ€™ a prospective 2-year cohort study. <i>Clinical Nutrition</i> , 2021, 40, 4616-4623.	2.3	1
190	Pharmacist-specific guidelines for the medical management of GERD in adults*. <i>Canadian Pharmacists Journal</i> , 2008, 141, S10-S15.e3.	0.4	1
191	NutriSup-PPN: A Pilot Randomized Control Trial of Oral Nutritional Supplementation (ONS) and Peripheral Parenteral Nutrition (PPN) in Canadian, Malnourished, Hospitalized Patients.. <i>Clinical Nutrition ESPEN</i> , 2022, , .	0.5	1
192	New Pharmacologic Approaches in Gastroesophageal Reflux Disease. <i>Thoracic Surgery Clinics</i> , 2011, 21, 557-574.	0.4	0
193	Proton pump inhibitor versus placebo in the short term management of gastro-esophageal reflux disease. <i>The Cochrane Library</i> , 0, , .	1.5	0
194	Response to Atreja et al.. <i>American Journal of Gastroenterology</i> , 2015, 110, 346-347.	0.2	0
195	Communicating Gastrointestinal Symptoms: The Patientâ€™s Challenge. <i>Critical Reviews in Biomedical Engineering</i> , 2018, 46, 83-92.	0.5	0
196	Response to Comments on the CAG/CCC Position Statement on Biosimilars for Inflammatory Bowel Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 98-99.	0.1	0
197	Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, .	1.1	0
198	Declining Use of Corticosteroids for Crohnâ€™s Disease Has Implications for Study Recruitment: Results of a Pilot Randomized Controlled Trial. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 214-221.	0.1	0

#	ARTICLE	IF	CITATIONS
199	Letter to the Editor: Too Soon to Dismiss Inflammation-Related Differences in the Mucosa-Associated Microbiota in Crohn's Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2022, , .	0.9	0